SNA 120

Drug Profile

SNA 120

Alternative Names: CT 301/P; CT 327; K-252a-PEG2K; Pegylated K252A; SNA-120

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Cephalon
  • Developer Creabilis SA; Sienna Biopharmaceuticals
  • Class Antipsoriatics; Carbazoles; Indole alkaloids; Skin disorder therapies; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis
  • Discontinued Neuropathic pain

Most Recent Events

  • 21 Mar 2017 Discontinued - Phase-I for Neuropathic pain (In volunteers) in Denmark (Topical) (Sienna pipeline, March 2017)
  • 06 Dec 2016 Creabilis SA has been acquired by Sienna Biopharmaceuticals
  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top